Multi-Institutional Trial of Accelerated Hypofractionated Intensity-Modulated Radiation Therapy for Early-Stage Oropharyngeal Cancer (RTOG 00-22)

Avraham Eisbruch, Jonathan Harris, Adam S. Garden, Clifford K S Chao, William Straube, Paul M. Harari, Giuseppe Sanguineti, Christopher U. Jones, Walter R. Bosch, K. Kian Ang

Research output: Contribution to journalArticle

207 Citations (Scopus)

Abstract

Purpose: To assess the results of a multi-institutional study of intensity-modulated radiation therapy (IMRT) for early oropharyngeal cancer. Patients and Methods: Patients with oropharyngeal carcinoma Stage T1-2, N0-1, M0 requiring treatment of the bilateral neck were eligible. Chemotherapy was not permitted. Prescribed planning target volumes (PTVs) doses to primary tumor and involved nodes was 66 Gy at 2.2 Gy/fraction over 6 weeks. Subclinical PTVs received simultaneously 54-60 Gy at 1.8-2.0 Gy/fraction. Participating institutions were preapproved for IMRT, and quality assurance review was performed by the Image-Guided Therapy Center. Results: 69 patients were accrued from 14 institutions. At median follow-up for surviving patients (2.8 years), the 2-year estimated local-regional failure (LRF) rate was 9%. 2/4 patients (50%) with major underdose deviations had LRF compared with 3/49 (6%) without such deviations (p = 0.04). All cases of LRF, metastasis, or second primary cancer occurred among patients who were current/former smokers, and none among patients who never smoked. Maximal late toxicities Grade ≥2 were skin 12%, mucosa 24%, salivary 67%, esophagus 19%, osteoradionecrosis 6%. Longer follow-up revealed reduced late toxicity in all categories. Xerostomia Grade ≥2 was observed in 55% of patients at 6 months but reduced to 25% and 16% at 12 and 24 months, respectively. In contrast, salivary output did not recover over time. Conclusions: Moderately accelerated hypofractionatd IMRT without chemotherapy for early oropharyngeal cancer is feasible, achieving high tumor control rates and reduced salivary toxicity compared with similar patients in previous Radiation Therapy Oncology Group studies. Major target underdose deviations were associated with higher LRF rate.

Original languageEnglish
Pages (from-to)1333-1338
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume76
Issue number5
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Oropharyngeal Neoplasms
radiation therapy
Radiotherapy
cancer
toxicity
chemotherapy
deviation
planning
grade
tumors
Osteoradionecrosis
esophagus
Drug Therapy
Xerostomia
Radiation Oncology
Second Primary Neoplasms
assurance
metastasis
Esophagus
therapy

Keywords

  • Head-and-neck cancer
  • Intensity-modulated radiation therapy
  • Oropharynx cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Multi-Institutional Trial of Accelerated Hypofractionated Intensity-Modulated Radiation Therapy for Early-Stage Oropharyngeal Cancer (RTOG 00-22). / Eisbruch, Avraham; Harris, Jonathan; Garden, Adam S.; Chao, Clifford K S; Straube, William; Harari, Paul M.; Sanguineti, Giuseppe; Jones, Christopher U.; Bosch, Walter R.; Ang, K. Kian.

In: International Journal of Radiation Oncology Biology Physics, Vol. 76, No. 5, 04.2010, p. 1333-1338.

Research output: Contribution to journalArticle

Eisbruch, Avraham ; Harris, Jonathan ; Garden, Adam S. ; Chao, Clifford K S ; Straube, William ; Harari, Paul M. ; Sanguineti, Giuseppe ; Jones, Christopher U. ; Bosch, Walter R. ; Ang, K. Kian. / Multi-Institutional Trial of Accelerated Hypofractionated Intensity-Modulated Radiation Therapy for Early-Stage Oropharyngeal Cancer (RTOG 00-22). In: International Journal of Radiation Oncology Biology Physics. 2010 ; Vol. 76, No. 5. pp. 1333-1338.
@article{7dac0ad58ed04123a552446f626b9287,
title = "Multi-Institutional Trial of Accelerated Hypofractionated Intensity-Modulated Radiation Therapy for Early-Stage Oropharyngeal Cancer (RTOG 00-22)",
abstract = "Purpose: To assess the results of a multi-institutional study of intensity-modulated radiation therapy (IMRT) for early oropharyngeal cancer. Patients and Methods: Patients with oropharyngeal carcinoma Stage T1-2, N0-1, M0 requiring treatment of the bilateral neck were eligible. Chemotherapy was not permitted. Prescribed planning target volumes (PTVs) doses to primary tumor and involved nodes was 66 Gy at 2.2 Gy/fraction over 6 weeks. Subclinical PTVs received simultaneously 54-60 Gy at 1.8-2.0 Gy/fraction. Participating institutions were preapproved for IMRT, and quality assurance review was performed by the Image-Guided Therapy Center. Results: 69 patients were accrued from 14 institutions. At median follow-up for surviving patients (2.8 years), the 2-year estimated local-regional failure (LRF) rate was 9{\%}. 2/4 patients (50{\%}) with major underdose deviations had LRF compared with 3/49 (6{\%}) without such deviations (p = 0.04). All cases of LRF, metastasis, or second primary cancer occurred among patients who were current/former smokers, and none among patients who never smoked. Maximal late toxicities Grade ≥2 were skin 12{\%}, mucosa 24{\%}, salivary 67{\%}, esophagus 19{\%}, osteoradionecrosis 6{\%}. Longer follow-up revealed reduced late toxicity in all categories. Xerostomia Grade ≥2 was observed in 55{\%} of patients at 6 months but reduced to 25{\%} and 16{\%} at 12 and 24 months, respectively. In contrast, salivary output did not recover over time. Conclusions: Moderately accelerated hypofractionatd IMRT without chemotherapy for early oropharyngeal cancer is feasible, achieving high tumor control rates and reduced salivary toxicity compared with similar patients in previous Radiation Therapy Oncology Group studies. Major target underdose deviations were associated with higher LRF rate.",
keywords = "Head-and-neck cancer, Intensity-modulated radiation therapy, Oropharynx cancer",
author = "Avraham Eisbruch and Jonathan Harris and Garden, {Adam S.} and Chao, {Clifford K S} and William Straube and Harari, {Paul M.} and Giuseppe Sanguineti and Jones, {Christopher U.} and Bosch, {Walter R.} and Ang, {K. Kian}",
year = "2010",
month = "4",
doi = "10.1016/j.ijrobp.2009.04.011",
language = "English",
volume = "76",
pages = "1333--1338",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Multi-Institutional Trial of Accelerated Hypofractionated Intensity-Modulated Radiation Therapy for Early-Stage Oropharyngeal Cancer (RTOG 00-22)

AU - Eisbruch, Avraham

AU - Harris, Jonathan

AU - Garden, Adam S.

AU - Chao, Clifford K S

AU - Straube, William

AU - Harari, Paul M.

AU - Sanguineti, Giuseppe

AU - Jones, Christopher U.

AU - Bosch, Walter R.

AU - Ang, K. Kian

PY - 2010/4

Y1 - 2010/4

N2 - Purpose: To assess the results of a multi-institutional study of intensity-modulated radiation therapy (IMRT) for early oropharyngeal cancer. Patients and Methods: Patients with oropharyngeal carcinoma Stage T1-2, N0-1, M0 requiring treatment of the bilateral neck were eligible. Chemotherapy was not permitted. Prescribed planning target volumes (PTVs) doses to primary tumor and involved nodes was 66 Gy at 2.2 Gy/fraction over 6 weeks. Subclinical PTVs received simultaneously 54-60 Gy at 1.8-2.0 Gy/fraction. Participating institutions were preapproved for IMRT, and quality assurance review was performed by the Image-Guided Therapy Center. Results: 69 patients were accrued from 14 institutions. At median follow-up for surviving patients (2.8 years), the 2-year estimated local-regional failure (LRF) rate was 9%. 2/4 patients (50%) with major underdose deviations had LRF compared with 3/49 (6%) without such deviations (p = 0.04). All cases of LRF, metastasis, or second primary cancer occurred among patients who were current/former smokers, and none among patients who never smoked. Maximal late toxicities Grade ≥2 were skin 12%, mucosa 24%, salivary 67%, esophagus 19%, osteoradionecrosis 6%. Longer follow-up revealed reduced late toxicity in all categories. Xerostomia Grade ≥2 was observed in 55% of patients at 6 months but reduced to 25% and 16% at 12 and 24 months, respectively. In contrast, salivary output did not recover over time. Conclusions: Moderately accelerated hypofractionatd IMRT without chemotherapy for early oropharyngeal cancer is feasible, achieving high tumor control rates and reduced salivary toxicity compared with similar patients in previous Radiation Therapy Oncology Group studies. Major target underdose deviations were associated with higher LRF rate.

AB - Purpose: To assess the results of a multi-institutional study of intensity-modulated radiation therapy (IMRT) for early oropharyngeal cancer. Patients and Methods: Patients with oropharyngeal carcinoma Stage T1-2, N0-1, M0 requiring treatment of the bilateral neck were eligible. Chemotherapy was not permitted. Prescribed planning target volumes (PTVs) doses to primary tumor and involved nodes was 66 Gy at 2.2 Gy/fraction over 6 weeks. Subclinical PTVs received simultaneously 54-60 Gy at 1.8-2.0 Gy/fraction. Participating institutions were preapproved for IMRT, and quality assurance review was performed by the Image-Guided Therapy Center. Results: 69 patients were accrued from 14 institutions. At median follow-up for surviving patients (2.8 years), the 2-year estimated local-regional failure (LRF) rate was 9%. 2/4 patients (50%) with major underdose deviations had LRF compared with 3/49 (6%) without such deviations (p = 0.04). All cases of LRF, metastasis, or second primary cancer occurred among patients who were current/former smokers, and none among patients who never smoked. Maximal late toxicities Grade ≥2 were skin 12%, mucosa 24%, salivary 67%, esophagus 19%, osteoradionecrosis 6%. Longer follow-up revealed reduced late toxicity in all categories. Xerostomia Grade ≥2 was observed in 55% of patients at 6 months but reduced to 25% and 16% at 12 and 24 months, respectively. In contrast, salivary output did not recover over time. Conclusions: Moderately accelerated hypofractionatd IMRT without chemotherapy for early oropharyngeal cancer is feasible, achieving high tumor control rates and reduced salivary toxicity compared with similar patients in previous Radiation Therapy Oncology Group studies. Major target underdose deviations were associated with higher LRF rate.

KW - Head-and-neck cancer

KW - Intensity-modulated radiation therapy

KW - Oropharynx cancer

UR - http://www.scopus.com/inward/record.url?scp=77949564251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949564251&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2009.04.011

DO - 10.1016/j.ijrobp.2009.04.011

M3 - Article

C2 - 19540060

AN - SCOPUS:77949564251

VL - 76

SP - 1333

EP - 1338

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -